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Background: Lung adenocarcinoma (LAC), the primary histological type of non-small cell lung cancer (NSCLC), has
displayed an increasing incidence and mortality worldwide. However, therapeutic approaches were limited. Dysregulation
of some lncRNAs has been shown in various types of cancers including LAC. The aim of the present study was to vertify
lncRNA DLX6-AS1 expression in LAC.
Methods: Microarray assay revealed expression profile of lncRNAs in LAC. qRT-PCR ( quantitative reverse transcription
PCR) was performed to identify lncRNA DLX6-AS1 expression level in 72 paired LAC and adjacent normal lung tissues.
qRT-PCR and Western blotting were used to verify that down-regulation lncRNA DLX6-AS1 decreased DLX6 (distal-less
homeobox 6) mRNA and protein expression.
Results: Microarray analysis identified up-regulation of 272 lncRNAs and down-regulation of 635 lncRNAs in LAC tissues.
The expression level of lncRNA DLX6-AS1 in LAC tissues was significantly higher compared to paired adjacent normal lung
tissues (P< 0.05). In addition, its expression level was closed correlated with both histological differentiation (P = 0.004) and
TNM stage (P = 0.033). qRT-PCR and Western blotting analysis showed that DLX6 mRNA and protein levels were lower in
si-LncRNA group than in the NC (negative control) and Blank groups.
Conclusions: Microarray analysis identified that lncRNA DLX6-AS1 was up-regulated in LAC tissues. High DLX6-AS1
expression levels were significantly associated with both histological differentiation and TNM stage. Down-regulation of
lncRNA DLX6-AS1 expression decreased the DLX6 mRNA and protein levels.
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With an ascending incidence in recent year, lung cancer is
now the mostly commonly diagnosed malignancy world-
wide, representing the leading cause of cancer-related
death [1-3]. In 2014, an estimated 224,210 new cases will
be diagnosed, of which the majority are probably non-
small cell lung cancer (NSCLC) and at advanced stage
meanwhile [4]. NSCLC including adenocarcinoma and
squamous cell carcinoma, is a predominant form of lung
cancer [5]. Despite the improvement achieved in chemo-
therapy and radiotherapy over the past few decades, the
prognosis for patients with NSCLC is still dismal, with
5-year survival rate slightly more than 15% [6]. Lung* Correspondence: gjzhangzzu@126.com
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all NSCLC and its incidence has been increasing
recently [6,7]. Thus, it is urgent to find new prognostic
markers and therapeutic strategies to improve the
present situation. Recently, growing evidence indicates
that non-coding RNAs may be involved in cancer
pathogenesis, providing new insights into the biological
progress of LAC [8,9].
The human genome project revealed that at least 90%
of the human genome is actively transcribed to RNA, but
less than 2% of RNA encodes proteins [10,11]. Non-
coding RNAs (ncRNAs), including microRNAs (miRNAs),
long non-coding RNAs (lncRNAs), tRNAs, snoRNAs, and
siRNAs, are functional RNAs that don’t encode proteins
[12,13]. LncRNAs are known to play important roles
during cellular development and differentiation, and a
large range of biological processes, such as modulation ofdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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of induced pluripotent stemcells [14,15]. Dysregulation
of some lncRNAs has been shown in various diseases
including cancers, such as breast cancer, hepatocellular
carcinoma, melanoma, bladder cancer, prostate cancer,
gastric cancer and skin cancer [16-27]. For example,
HOTAIR, has been determined as a negative prognostic
indicator in breast, liver and pancreatic cancer, repre-
senting a close association especially with breast cancer
metastasis [28,29]. Takahashi’s study demonstrated that
PVT1 expression levels in colorectal cancer tissues were
significantly higher than that in non-cancerous tissue,
and patients with high PVT1 expression had a signifi-
cantly poorer prognosis, what’s more, knockdown PVT1
expression could promotes apoptosis in colorectal cancer
cells [30]. Metastasis associated lung adenocarcinoma
transcript 1 (MALAT1) was found to be over expressed
not only in breast, pancreas, colon, prostate, and liver can-
cers, but also in early-stage metastasizing NSCLC [31,32].
However, the functions of lncRNAs in lung cancer re-
main unclear. We investigated microarray data of lncRNAs
from 3 paired LAC tissues and adjacent normal tissues,
then focused on lncRNA DLX6-AS1 (distal-less homeobox
6 antisense 1). Up to now, there is no relevant report about
the relationship between lncRNA DLX6-AS1 and the
progression of LAC. The aim of the present study was
to vertify lncRNA DLX6-AS1 expression in LAC tissues
and adjacent normal tissues, then to explore the rela-
tionship between lncRNA DLX6-AS1 expression and
clinicopathological features and to test the expression
of DLX6 mRNA and protein in LAC cell lines after
transfection with siRNA of lncRNA DLX6-AS1. The
study may provide a new perspective on the diagnosis
and treatment for this deadly disease.
Results
Microarray data analysis
A total of 907 lncRNAs were demonstrated with differ-
ential expressions (Log2fold change (T/N ≥2 or ≤ −2)Table 1 Part of lncRNAs detected using microarray in three L
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HOTAIR 2.581743between tumor tissues and adjacent normal tissues from
3 LAC patients. Microarray analysis identified that 272
lncRNAs were up-regulated including lncRNA DLX6-
AS1, whereas 635 lncRNAs were down-regulated in LAC
tissues. Part of lncRNAs expression levels are shown in
Table 1. The heat map of the hierarchical clustering results
was performed to vertify part of the distinguishable
lncRNAs expression profile among 3 paired LAC and ad-
jacent normal tissues (Figure 1a). The scatterplot results
showed that the distribution and expression variation of
the log 2 ratios of lncRNAs were similar among 3 paired
LAC and adjacent normal tissues (Figure 1b). KEGG path-
way analysis revealed that lncRNA DLX6-AS1was in-
volved in cell proliferation process through JAK/STAT
signaling pathway (Figure 1c). The molecular mechanism
will be clarified in our further study.
Correlation between lncRNA DLX6-AS1 expression levels
and clinical characteristics
GO annotation and KEGG pathway analysis indicated
that aberrantly expressed of lncRNA DLX6-AS1 affected
biological processes of lung adenocarcinoma. To validate
the microarray data, we analyzed DLX6-AS1 expression
in 72 paired LAC and adjacent normal lung tissues using
qRT-PCR. We calculated the relative expression of lncRNA
with the comparative cycle threshold (Ct) (2−ΔCt) method,
and fold changes of ≥2 were designated as up-regulated.
Up-regulation of DLX6-AS1 was detected in 83.33%
(60/72) of LAC tissues compared with adjacent normal
tissues, while 16.67% (12/72) displayed either down-
regulation or unobvious alteration. DLX6-AS1 expres-
sion in LAC tissues was conclusively proved a higher
level than that in paired adjacent normal lung tissues
(Z = −7.273, P = 0.000, Figure 2a), while DLX6 mRNA
showed a similar trend (Z = −7.374, P = 0.000, Figure 2d).
Statistical analysis revealed that DLX6-AS1 and DLX6
mRNA expression levels were significantly associated with
both histological differentiation (P = 0.004, Figure 2b;
P = 0.000, Figure 2e) and TNM stage (P = 0.033, Figure 2c;AC patients
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Figure 1 Microarray data analysis. a The result from Hierarchical Clustering showed part of the distinguishable lncRNA expression profiles among
3 paired LAC and adjacent normal tissues. “Red” indicates high relative expression; and “green” indicates low relative expression. b The scatter-plot was
used for assessing the lncRNA expression variation among 3 paired LAC and adjacent normal tissues. The values of x-axis and y-axis in the scatter-plot
were the normalized signal values of each sample (log 2 scaled). The green lines are fold change lines (the default fold change value given is 2.0). The
lncRNAs above the top green line and below the bottom green line indicated > 2.0-fold change in expression of lncRNAs among the 3 compared
samples. “Red” denotes high relative expression levels, and “blue” denotes low relative expression levels. c KEGG pathway analysis revealed that
lncRNA DLX6-AS1was involved in cell proliferation process with JAK/STAT signaling pathway. The yellow squares represent key elements in cell
proliferation progression.
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clinicopathological features including age, gender, and
lymph node metastasis (Table 2).
Down-regulation the expression of lncRNA DLX6-AS1
decreased DLX6 mRNA and protein levels
In most samples, the expression levels of lncRNA
DLX6-AS1 were higher in tumor tissues than adjacent
normal tissues. Thus, we speculated that DLX6-AS1 was
an oncogene and knockdown of DLX6-AS1 decreasedDLX6 expression. To test it, we investigated the changes
of DLX6 mRNA and protein levels after A549 and
H1650 cells were transfected with siRNA targeting
lncRNA DLX6-AS1 (si-LncRNA groups), negative con-
trol (NC groups) blank. Blank group were set as well.
qRT-PCR analysis revealed that lncRNA DLX6-AS1
expression levels in si-LncRNA groups were significantly
lower, compared to NC and Blank groups (Figure 3a:
A549,χ2 = 19.481, P = 0.000; Figure 3d: H1650, χ2 = 19.564,
P = 0.001 ). qRT-PCR and Western blotting analysis showed
Figure 2 The expression levels of lncRNA DLX6-AS1 in lung adenocarcinoma tissues and adjacent normal lung tissues. a The expression levels of
lncRNA DLX6-AS1 in paired LAC tissues and adjacent normal lung tissues were determined by qRT-PCR (2−ΔCt). Statistically significant differences
were observed (*P< 0.05). b LncRNA DLX6-AS1 expression levels were significantly associated with histological differentiation (*P< 0.05). c The
expression levels of lncRNA DLX6-AS1 were associated with TNM stage (*P< 0.05). d DLX6 mRNA levels in paired LAC tissues and adjacent normal
lung tissues were determined by qRT-PCR(*P< 0.05). e DLX6 mRNA levels were significantly associated with histological differentiation (*P< 0.05).
f DLX6 mRNA levels were associated with TNM stage (*P< 0.05). Tumor: tumor tissue; Normal: adjacent normal lung tissue.








Median ± SD P-Vale Media ± SD P-Value
Gender
Male 35 0.6452±0.1905 0.249 2.5103±0.4123 0.149
Female 37 0.6926±0.1541 2.6941±0.6363
Age (years)
≥60 34 0.6762±0.1837 0.762 2.6426±0.6820 0.591
<60 38 0.6637±0.1655 2.5709±0.3863
Differentiation
Well 27 0.5965±0.2017 0.004* 2.2947±0.3855 0.000*
Moderate 33 0.6873±0.1510 2.7153±0.5559
Poor 12 0.7852±0.4988 2.9984±0.4624
Lymph node metastasis
Positive 33 0.7078±0.1259 0.075 2.7230±0.5027 0.087
Negative 39 0.6373±0.2009 2.5047±0.5625
TNM stage
I 18 0.5806±0.1533 0.033* 2.3290±0.3853 0.001*
II 36 0.6897±0.1806 2.5641±0.4939
III 18 0.7184±0.1512 2.9618±0.6028
*Indicated statistical significance (P< 0.05).
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Figure 3 Down-regulation the expression of lncRNA DLX6-AS1 decreased the DLX6 protein levels. a Using qRT-PCR analysis in A549 cells, the
expression levels of lncRNA DLX6-AS1 in si-LncRNA group were significantly lower, compared to NC and Blank groups (*P< 0.05). b DLX6 mRNA
expression in si-LncRNA group was also lower than in the NC and Blank groups in A549 cells by qRT-PCR (*P< 0.05). c Western blotting analysis
showed that DLX6 protein levels in si-LncRNA group were also lower than NC and Blank groups in A549 cells (*P< 0.05). β-actin was used as an
endogenous reference. d qRT-PCR analysis verified that the expression level of lncRNA DLX6-AS1 in si-LncRNA group was significantly lower,
compared to NC and Blank groups in H1650 cells (*P< 0.05). e DLX6 mRNA expression in si-LncRNA group was also lower than in NC and Blank
groups in H1650 cells by qRT-PCR (*P< 0.05). f Western blotting analysis showed that DLX6 protein levels in si-LncRNA group were also lower than
in the NC and Blank groups in H1650 cells (*P< 0.05). si-LncRNA group: cells transfected with siRNA targeting lncRNA DLX6-AS1; NC group: cells
transfected with negative control siRNA; Blank group: non-transfected cells.
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lower in si-lncRNA groups than in NC and Blank groups
(Figure 3b, c, e, and f).
Discussion
In recent years, genome-wide surveys have revealed that
there are over 3000 human lncRNAs longer than 200 nt,
but less than 1% have been characterized [33,34]. Al-
though only a minority have been characterized in details,
recent studies have indicated that lncRNAs were key
players in gene regulatory processes and could influence
both normal and transformed cellular function [35,36].
Several studies have further demonstrated that lncRNAs
were efficiently regulated during cellular development
in response to diverse signalings, and dysregulation of
lncRNAs might also affect epigenetic information and pro-
vide advantages for cellular growth, resulting in progres-
sive and uncontrolled tumor growth [17,29,36,37]. Thus,
identification of tumor associated lncRNAs, which might
be novel therapeutic targets, is critical for recognizing the
roles of lncRNAs in tumorigenesis [38]. Based on micro-
array data analysis, our attention was focused on the
lncRNA DLX6-AS1.
DLX gene family contains a homeobox related to
Drosophila distal-less (Dll), a gene expressed in the headand limbs of developmental fruit fly. DLX genes, the
vertebrate homologues of Dll, comprise a family of homeo-
box transcription factors involved in cell differentiation
and morphogenesis. In humans, six distal-less homeobox
(DLX) genes exist, represented by three bi-gene clusters,
DLX1/DLX2, DLX5/DLX6, and DLX3/DLX4. Deregula-
tion of DLX genes, including DLX4 and DLX5, was found
in human solid tumors and hematologic malignancies,
which indicated that DLX played an important role in
tumor growth and progression [39-44]. So far, the
functions of DLX6 haven’t been reported in related re-
searches, not to mention its expression level and work-
ing mechanisms in lung cancer.
In this study, microarray analysis suggested that the
expression level of lncRNA DLX6-AS1 was higher in
three LAC tissues than that in the paired adjacent nor-
mal lung tissues. qRT-PCR was performed to investigate
lncRNA DLX6-AS1 expression levels in 72 LAC patients
who hadn’t received radiotherapy or chenmotherapy be-
fore. Correlation of lncRNA DLX6-AS1 expression levels
and clinicopathological characteristics was then ana-
lyzed. Results showed that DLX6-AS1 expression was
increased in LAC tissues compared with adjacent non-
tumor tissues, which indicated its possible participation
in carcinogenesis. Besides, DLX6-AS1 expression levels
Li et al. Cancer Cell International  (2015) 15:48 Page 6 of 8showed close correlation with LAC histological grade
and TNM stage. High DLX6-AS1 expression levels were
more likely to be detected in tumors with advanced
histological grade, and TNM III, suggesting that DLX6-
AS1 might participate in LAC invasion and metastasis.
Taken together all the evidences, DLX6-AS1 was pro-
posed to play a vital role in LAC carcinogenesis and pro-
gression. After transfection with siRNA of lncRNA
DLX6-AS1, qRT-PCR and Western blotting analysis dis-
covered that DLX6 mRNA and protein expression were
decreased in A549 and H1650 cells compared to the NC
and Blank groups. Based on our research data, lncRNA
DLX6-AS1 was probably a novel therapeutic target for
LAC patients. But the detailed molecular mechanism
remains unclear. Our further studies will put more
efforts on exploring the potential roles of lncRNA
DLX6-AS1 in LAC development.
Conclusions
Microarray analysis identified that lncRNA DLX6-AS1
was up-regulated in LAC tissues. High DLX6-AS1 expres-
sion levels were significantly associated with both histo-
logical differentiation and TNM stage. Down-regulation
of lncRNA DLX6-AS1 expression decreased the DLX6
mRNA and protein levels.
Materials and methods
Patient samples collection
72 paired LAC tissues and adjacent normal lung tissues
(located more than 5 cm away from the tumors) were
obtained from patients who underwent primary surgical
resections between March 2012 and January 2014 at the
First Affiliated Hospital of Zhengzhou University. None
of the patients had received preoperative adjuvant ther-
apy. Resected tissue samples were immediately frozen in
liquid nitrogen and stored at-80°C before RNA extrac-
tion. All the diagnoses of LAC and adjacent normal lung
tissues were histopathologically confirmed. Prior in-
formed consents and approval from the ethics commit-
tee of Zhengzhou University were obtained for the use
of clinical samples for research purposes.
Microarray assay
Paired cancer tissues and adjacent normal tissues from
three patients were randomly pooled and hybridized to
chips. LncRNA microarray assays were performed by
Biotechnology Corporation (Shanghai, China).Total RNA
was amplified and labeled by Low Input Quick Amp La-
beling Kit, One-Color (Agilent technologies), following
the manufacturer’s instructions. Labeled cDNA were
purified by RNeasy mini kit (QIAGEN, Germany). After
17 hours’ hybridization, slides were washed with Gene
Expression Wash Buffer Kit (Agilent technologies),
following the manufacturer’s instructions. Slides werescanned by Agilent Microarray Scanner (Agilent tech-
nologies) with default settings. Data were extracted with
Feature Extraction software 10.7 (Agilent technologies).
RNA extraction and quantitative real-time fluorescent
To further certify the generality of lncRNAs expression
pattern, specimens from 72 patients were used to per-
form qRT-PCR assay. Total RNA was extracted from
frozen specimens using TRIzol reagent (Invitrogen, USA)
according to the manufacturer’s protocol. qRT-PCR was
performed using an ABI 7500 thermal cycler, according to
the manufacturer’s recommendations. Each qRT-PCR
experiment was repeated three times. The primers se-
lected as the followings: lncRNA DLX6-AS1, forward,
5’-AGTTTCTCTCTAGATTGCCTT-3’; reverse, 5’-ATT
GACATGTTAGTGCCCTT -3’. DLX6, forward, 5’-TC
CACACCAGGACACGATGC-3’, reverse, 5’-CTTGCC
ACACTTATGAGCTCT-3’. GAPDH, forward, 5’-AGA
GGCAGGGATGATGTTCTG -3’ , reverse, 5’-GACTC
ATGACCACAGTCCATGC-3’. Relative expression of
genes was calculated using the comparative cycle threshold
(Ct) (2−ΔCt, ΔCt =Ct median lncRNA or mRNA-Ct median
GAPDH) method with glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), as the endogenous control [45].
Cell culture
Human lung adenocarcinoma cell lines A549 and H1650
were purchased from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). Cells
were cultured in RPMI1640 (Gibco, USA) medium sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin (Enpromise, China)
in humidified air with 5% CO2 at 37°C.
SiRNA transfection
Specific siRNAs targeting lncRNA DLX6-AS1 and the
negative control siRNAs were designed and synthesized
by GenePharma (Shanghai, China). Cells were plated in
6-well plates in antibiotic-free growth medium supple-
mented with 10% FBS and cultured until 50-70% confluent
overnight. The siRNAs were transfected into cultured cells
using Lipofectamine 2000 (Invitrogen, USA) according to
the manufacturer’s instructions. Forty-eight hours after
transfection, cells were harvested for qRT-PCR or Western
blotting analysis.
Western blotting
Cells were washed twice with PBS solution, and then
were lysed with RIPA Lysis Buffer (Beyotime, China)
containing phenylmethanesulfonylfluoride (PMSF). Pro-
tein concentrations were determined with Pierce BCA
Protein Assay Kit (Beyotime, Haimen, China). Proteins
were subjected to 12% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred
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1 h in phosphate-buffered saline/Tween-20 containing
5% non-fat milk. The membranes were incubated over-
night at 4°C with 1:500 dilutions of the primary anti-
bodies (rabbit anti-human DLX6 antibody, 1:500, Santa
Cruz Biotechnology). Following extensive washing with
TBST, secondary antibodies were incubated at room
temperature for 1 h (HRP labeled goat anti-rabbit IgG,
1:1000, Santa Cruz Biotechnology). Membranes were
washed with Tween 20-PBS four times (15 min each) at
room temperature. Signals were determined using a
chemiluminescence detection kit (Amersham Pharma-
cia Biotech, Piscataway, NJ). Protein levels were normal-
ized to β-actin.
Statistical analysis
Statistical analysis was conducted with the assistance of
SPSS 17.0 software. All data were expressed as means ±
standard deviation (SD). The differences between paired
samples were analyzed using Wilcoxon signed-rank test.
The differences between diverse independent groups were
analyzed using Kruskal-Wallis test. For multiple compari-
sons, Tamhane’T2 (M) was used in the comparison of the
parental and control vector groups. P< 0.05 was consid-
ered to be statistically significant.
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